ADC Therapeutics SA has released a corporate presentation highlighting its advancements and strategic direction in the field of antibody-drug conjugates (ADCs). The company emphasizes its specialized end-to-end capabilities from discovery to commercialization, aiming to enhance the therapeutic index of next-generation ADCs through an array of payloads, linkers, and conjugation chemistry. A key focus is on the expansion of the FDA-approved ZYNLONTA® for diffuse large B-cell lymphoma (DLBCL), including potential new indications and combination therapies. Additionally, ADC Therapeutics is pursuing early-stage development in solid tumors, targeting Claudin-6, PSMA, NaPi2b, and ASCT2. The company is also seeking research collaborations to broaden its portfolio. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。